Pfizer Opens Biotech Plant in Sweden

Pfizer says it has opened a previously announced new facility for biotechnological pharmaceutical production at Strangnas, Sweden. Pfizer expects the plant, which was built with an investment of about €150 million ($213 million), to further strengthen its capacities in the rapidly growing biotech sector. The plant is Sweden’s largest site for the production of biotechnological pharmaceuticals, Pfizer says. “Biologics hold tremendous promise in changing the way patients are treated and diseases prevented,” says Rory O’Connor...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers